Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 19:8:F1000 Faculty Rev-888.
doi: 10.12688/f1000research.18811.1. eCollection 2019.

The 6th World Symposium on Pulmonary Hypertension: what's old is new

David F Condon  1 , Nils P Nickel  1 , Ryan Anderson  1 , Shireen Mirza  1   2 , Vinicio A de Jesus Perez  1   2
Affiliations
Review

The 6th World Symposium on Pulmonary Hypertension: what's old is new

David F Condon et al. F1000Res. .

Abstract

In February 2018, the 6th World Symposium on Pulmonary Hypertension (WSPH) brought together experts from various disciplines to review the most relevant clinical and scientific advances in the field of PH over the last 5 years. Based on careful review and discussions by members of the different task forces, major revisions were made on the hemodynamic definition for various forms of PH and new genes were added to the list of genetic markers associated with pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease. In addition, the use of risk stratification tools was encouraged as a strategy to reduce one-year mortality risk in PAH patients through early implementation of PAH therapies. While members of the medical community are still debating some of the proposed changes, the new WSPH guidelines advocate early diagnosis and initiation of combination therapy to reduce mortality and improve quality of life in patients with PH.

Keywords: genetics; hemodynamics; pulmonary hypertension; therapy.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.Competing interests: Dr Simon is a consultant for Actelion, Complexa and received research funding from Novartis and NIH.Competing interests: Dr Sahay is serving as a speaker and consultant for Bayer, United Therapeutics and Actelion pharmaceuticals. He also has a Chest foundation grant.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Proposed algorithm for treatment of pulmonary arterial hypertension based on 6th World Symposium on Pulmonary Hypertension recommendations.
CCB, calcium channel blocker; ERA, endothelin receptor antagonist; NYHA, New York Heart Association; PDE5i, phosphodiesterase inhibitor.
See this image and copyright information in PMC

References

    1. Lüthy E: Proceedings: The epidemic of primary pulmonary hypertension in Europe. Pathol Microbiol (Basel). 1975;43(2–O):246–7. - PubMed
    1. Hatano S, Strasser T, World Health Organization: Primary pulmonary hypertension: report on a WHO meeting. Geneva;1975.
    1. Galiè N, McLaughlin VV, Rubin LJ, et al. : An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53(1): pii: 1802148. 10.1183/13993003.02148-2018 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Tielemans B, Delcroix M, Belge C, et al. : TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discov Today. 2019;24(3):703–16. 10.1016/j.drudis.2018.12.001 - DOI - PubMed

    2. F1000 Recommendation

    1. Austin ED, Loyd JE: The genetics of pulmonary arterial hypertension. Circ Res. 2014;115(1):189–202. 10.1161/CIRCRESAHA.115.303404 - DOI - PMC - PubMed

Publication types